Dysregulation and therapeutic targeting of RNA splicing in cancer.
Journal
Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
10
12
2021
accepted:
22
04
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
1
6
2022
Statut:
ppublish
Résumé
High-throughput sequencing and functional characterization of the cancer transcriptome have uncovered cancer-specific dysregulation of RNA splicing across a variety of cancers. Alterations in the cancer genome and dysregulation of RNA splicing factors lead to missplicing, splicing alteration-dependent gene expression and, in some cases, generation of novel splicing-derived proteins. Here, we review recent advances in our understanding of aberrant splicing in cancer pathogenesis and present strategies to harness cancer-specific aberrant splicing for therapeutic intent.
Identifiants
pubmed: 35624337
doi: 10.1038/s43018-022-00384-z
pii: 10.1038/s43018-022-00384-z
pmc: PMC9551392
mid: NIHMS1836796
doi:
Substances chimiques
RNA Splicing Factors
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
536-546Subventions
Organisme : NCI NIH HHS
ID : T32 CA009207
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA254838
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128239
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA251138
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA242020
Pays : United States
Informations de copyright
© 2022. Springer Nature America, Inc.
Références
Nilsen, T. W. & Graveley, B. R. Expansion of the eukaryotic proteome by alternative splicing. Nature 463, 457–463 (2010).
pubmed: 20110989
pmcid: 3443858
doi: 10.1038/nature08909
Wang, E. T. et al. Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470–476 (2008).
pubmed: 18978772
pmcid: 2593745
doi: 10.1038/nature07509
Brody, E. & Abelson, J. The ‘spliceosome’: yeast pre-messenger RNA associates with a 40S complex in a splicing-dependent reaction. Science 228, 963–967 (1985).
pubmed: 3890181
doi: 10.1126/science.3890181
Will, C. L. & Luhrmann, R. Spliceosome structure and function. Cold Spring Harb. Perspect. Biol. 3, a003707 (2011).
El Marabti, E., Malek, J. & Younis, I. Minor intron splicing from basic science to disease. Int. J. Mol. Sci. 22, 6062 (2021).
Agafonov, D. E. et al. Molecular architecture of the human U4/U6.U5 tri-snRNP. Science 351, 1416–1420 (2016).
pubmed: 26912367
doi: 10.1126/science.aad2085
Fica, S. M. Cryo-EM snapshots of the human spliceosome reveal structural adaptions for splicing regulation. Curr. Opin. Struct. Biol. 65, 139–148 (2020).
pubmed: 32717639
doi: 10.1016/j.sbi.2020.06.018
Nguyen, T. H. et al. The architecture of the spliceosomal U4/U6.U5 tri-snRNP. Nature 523, 47–52 (2015).
pubmed: 26106855
pmcid: 4536768
doi: 10.1038/nature14548
Pan, Q., Shai, O., Lee, L. J., Frey, B. J. & Blencowe, B. J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40, 1413–1415 (2008).
pubmed: 18978789
doi: 10.1038/ng.259
Gerstein, M. B. et al. Comparative analysis of the transcriptome across distant species. Nature 512, 445–448 (2014).
pubmed: 25164755
pmcid: 4155737
doi: 10.1038/nature13424
Braberg, H. et al. From structure to systems: high-resolution, quantitative genetic analysis of RNA polymerase II. Cell 154, 775–788 (2013).
pubmed: 23932120
pmcid: 3932829
doi: 10.1016/j.cell.2013.07.033
Howard, J. M. & Sanford, J. R. The RNAissance family: SR proteins as multifaceted regulators of gene expression. Wiley Interdiscip. Rev. RNA 6, 93–110 (2015).
pubmed: 25155147
doi: 10.1002/wrna.1260
Thibault, P. A. et al. hnRNP A/B proteins: an encyclopedic assessment of their roles in homeostasis and disease. Biology 10, 712 (2021).
pubmed: 34439945
pmcid: 8389229
doi: 10.3390/biology10080712
Van Nostrand, E. L. et al. A large-scale binding and functional map of human RNA-binding proteins. Nature 583, 711–719 (2020).
pubmed: 32728246
pmcid: 7410833
doi: 10.1038/s41586-020-2077-3
Schwerk, C. & Schulze-Osthoff, K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol. Cell 19, 1–13 (2005).
pubmed: 15989960
doi: 10.1016/j.molcel.2005.05.026
Jiang, Z. H., Zhang, W. J., Rao, Y. & Wu, J. Y. Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors. Proc. Natl Acad. Sci. USA 95, 9155–9160 (1998).
pubmed: 9689050
pmcid: 21308
doi: 10.1073/pnas.95.16.9155
Wu, J. Y., Tang, H. & Havlioglu, N. Alternative pre-mRNA splicing and regulation of programmed cell death. Prog. Mol. Subcell. Biol. 31, 153–185 (2003).
pubmed: 12494766
doi: 10.1007/978-3-662-09728-1_6
Kedzierska, H. & Piekielko-Witkowska, A. Splicing factors of SR and hnRNP families as regulators of apoptosis in cancer. Cancer Lett. 396, 53–65 (2017).
pubmed: 28315432
doi: 10.1016/j.canlet.2017.03.013
Boise, L. H. et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597–608 (1993).
pubmed: 8358789
doi: 10.1016/0092-8674(93)90508-N
Dou, Z. et al. Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation. J. Exp. Clin. Cancer Res. 40, 194 (2021).
pubmed: 34118966
pmcid: 8196531
doi: 10.1186/s13046-021-02001-w
Kim, J. H. et al. MCL-1ES, a novel variant of MCL-1, associates with MCL-1L and induces mitochondrial cell death. FEBS Lett. 583, 2758–2764 (2009).
pubmed: 19683529
doi: 10.1016/j.febslet.2009.08.006
Supek, F., Minana, B., Valcarcel, J., Gabaldon, T. & Lehner, B. Synonymous mutations frequently act as driver mutations in human cancers. Cell 156, 1324–1335 (2014).
pubmed: 24630730
doi: 10.1016/j.cell.2014.01.051
Jung, H. et al. Intron retention is a widespread mechanism of tumor-suppressor inactivation. Nat. Genet. 47, 1242–1248 (2015).
pubmed: 26437032
doi: 10.1038/ng.3414
Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64–69 (2011).
pubmed: 21909114
doi: 10.1038/nature10496
Papaemmanuil, E. et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365, 1384–1395 (2011).
pubmed: 21995386
pmcid: 3322589
doi: 10.1056/NEJMoa1103283
Wang, L. et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365, 2497–2506 (2011).
pubmed: 22150006
pmcid: 3685413
doi: 10.1056/NEJMoa1109016
Graubert, T. A. et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat. Genet. 44, 53–57 (2011).
pubmed: 22158538
pmcid: 3247063
doi: 10.1038/ng.1031
Harbour, J. W. et al. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat. Genet. 45, 133–135 (2013).
pubmed: 23313955
pmcid: 3789378
doi: 10.1038/ng.2523
Quesada, V. et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44, 47–52 (2011).
pubmed: 22158541
doi: 10.1038/ng.1032
Martin, M. et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat. Genet. 45, 933–936 (2013).
pubmed: 23793026
pmcid: 4307600
doi: 10.1038/ng.2674
Karni, R. et al. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 14, 185–193 (2007).
pubmed: 17310252
pmcid: 4595851
doi: 10.1038/nsmb1209
Anczukow, O. et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat. Struct. Mol. Biol. 19, 220–228 (2012).
pubmed: 22245967
pmcid: 3272117
doi: 10.1038/nsmb.2207
Danan-Gotthold, M. et al. Identification of recurrent regulated alternative splicing events across human solid tumors. Nucleic Acids Res. 43, 5130–5144 (2015).
pubmed: 25908786
pmcid: 4446417
doi: 10.1093/nar/gkv210
Chen, L., Tovar-Corona, J. M. & Urrutia, A. O. Increased levels of noisy splicing in cancers, but not for oncogene-derived transcripts. Hum. Mol. Genet. 20, 4422–4429 (2011).
pubmed: 21862452
pmcid: 3196890
doi: 10.1093/hmg/ddr370
Kahles, A. et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell 34, 211–224 (2018).
pubmed: 30078747
doi: 10.1016/j.ccell.2018.07.001
Seiler, M. et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 23, 282–296 (2018).
pubmed: 29617667
pmcid: 5933844
doi: 10.1016/j.celrep.2018.01.088
Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353–360 (2012).
pubmed: 22722193
pmcid: 3383766
doi: 10.1038/nature11143
The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399–405 (2012).
pubmed: 23103869
pmcid: 3530898
doi: 10.1038/nature11547
Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107–1120 (2012).
pubmed: 22980975
pmcid: 3557932
doi: 10.1016/j.cell.2012.08.029
Chen, S., Benbarche, S. & Abdel-Wahab, O. Splicing factor mutations in hematologic malignancies. Blood 138, 599–612 (2021).
pubmed: 34157091
doi: 10.1182/blood.2019004260
Cretu, C. et al. Molecular architecture of SF3b and structural consequences of its cancer-related mutations. Mol. Cell 64, 307–319 (2016).
pubmed: 27720643
doi: 10.1016/j.molcel.2016.08.036
Teng, T. et al. Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A–SF3b complex. Nat. Commun. 8, 15522 (2017).
pubmed: 28541300
pmcid: 5458519
doi: 10.1038/ncomms15522
Malcovati, L. et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood 136, 157–170 (2020).
pubmed: 32347921
pmcid: 7362582
doi: 10.1182/blood.2020004850
Dalton, W. B. et al. The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing. Blood Adv. 4, 1192–1196 (2020).
pubmed: 32211880
pmcid: 7160262
doi: 10.1182/bloodadvances.2019001127
Darman, R. B. et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 3′ splice site selection through use of a different branch point. Cell Rep. 13, 1033–1045 (2015).
pubmed: 26565915
doi: 10.1016/j.celrep.2015.09.053
DeBoever, C. et al. Transcriptome sequencing reveals potential mechanism of cryptic 3′ splice site selection in SF3B1-mutated cancers. PLoS Comput. Biol. 11, e1004105 (2015).
pubmed: 25768983
pmcid: 4358997
doi: 10.1371/journal.pcbi.1004105
Boultwood, J. et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS ONE 3, e1970 (2008).
pubmed: 18398482
pmcid: 2276313
doi: 10.1371/journal.pone.0001970
Nikpour, M. et al. The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia 27, 889–896 (2013).
pubmed: 23070040
doi: 10.1038/leu.2012.298
Inoue, D. et al. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature 574, 432–436 (2019).
pubmed: 31597964
pmcid: 6858563
doi: 10.1038/s41586-019-1646-9
Clough, C. A. et al. Coordinated mis-splicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome. Blood 139, 2038–2048 (2021).
doi: 10.1182/blood.2021012652
Lieu, Y. K. et al. SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. Proc. Natl Acad. Sci. USA 119, e2111703119 (2022).
Zhang, J. et al. Disease-causing mutations in SF3B1 alter splicing by disrupting interaction with SUGP1. Mol. Cell 76, 82–95 (2019).
pubmed: 31474574
pmcid: 7065273
doi: 10.1016/j.molcel.2019.07.017
Liu, Z. et al. Pan-cancer analysis identifies mutations in SUGP1 that recapitulate mutant SF3B1 splicing dysregulation. Proc. Natl Acad. Sci. USA 117, 10305–10312 (2020).
pubmed: 32332164
pmcid: 7229667
doi: 10.1073/pnas.1922622117
Gozani, O., Potashkin, J. & Reed, R. A potential role for U2AF–SAP 155 interactions in recruiting U2 snRNP to the branch site. Mol. Cell. Biol. 18, 4752–4760 (1998).
pubmed: 9671485
pmcid: 109061
doi: 10.1128/MCB.18.8.4752
Merendino, L., Guth, S., Bilbao, D., Martinez, C. & Valcarcel, J. Inhibition of msl-2 splicing by sex-lethal reveals interaction between U2AF35 and the 3′ splice site AG. Nature 402, 838–841 (1999).
pubmed: 10617208
doi: 10.1038/45602
Wu, S., Romfo, C. M., Nilsen, T. W. & Green, M. R. Functional recognition of the 3′ splice site AG by the splicing factor U2AF35. Nature 402, 832–835 (1999).
pubmed: 10617206
doi: 10.1038/45590
Reed, R. The organization of 3′ splice-site sequences in mammalian introns. Genes Dev. 3, 2113–2123 (1989).
pubmed: 2628164
doi: 10.1101/gad.3.12b.2113
Haferlach, T. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241–247 (2014).
pubmed: 24220272
doi: 10.1038/leu.2013.336
Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616–3627 (2013).
pubmed: 24030381
pmcid: 3837510
doi: 10.1182/blood-2013-08-518886
Ilagan, J. O. et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 25, 14–26 (2015).
pubmed: 25267526
pmcid: 4317169
doi: 10.1101/gr.181016.114
Wheeler, E. C. et al. Integrative RNA-omics discovers GNAS alternative splicing as a phenotypic driver of splicing factor-mutant neoplasms. Cancer Discov. 12, 836–855 (2021).
doi: 10.1158/2159-8290.CD-21-0508
Smith, M. A. et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat. Cell Biol. 21, 640–650 (2019).
pubmed: 31011167
pmcid: 6679973
doi: 10.1038/s41556-019-0314-5
Thol, F. et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 119, 3578–3584 (2012).
pubmed: 22389253
doi: 10.1182/blood-2011-12-399337
Desai, P. et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat. Med. 24, 1015–1023 (2018).
pubmed: 29988143
pmcid: 6849383
doi: 10.1038/s41591-018-0081-z
Graveley, B. R. & Maniatis, T. Arginine/serine-rich domains of SR proteins can function as activators of pre-mRNA splicing. Mol. Cell 1, 765–771 (1998).
pubmed: 9660960
doi: 10.1016/S1097-2765(00)80076-3
Liu, H. X., Chew, S. L., Cartegni, L., Zhang, M. Q. & Krainer, A. R. Exonic splicing enhancer motif recognized by human SC35 under splicing conditions. Mol. Cell. Biol. 20, 1063–1071 (2000).
pubmed: 10629063
pmcid: 85223
doi: 10.1128/MCB.20.3.1063-1071.2000
Schaal, T. D. & Maniatis, T. Multiple distinct splicing enhancers in the protein-coding sequences of a constitutively spliced pre-mRNA. Mol. Cell. Biol. 19, 261–273 (1999).
pubmed: 9858550
pmcid: 83884
doi: 10.1128/MCB.19.1.261
Daubner, G. M., Clery, A., Jayne, S., Stevenin, J. & Allain, F. H. A syn-anti conformational difference allows SRSF2 to recognize guanines and cytosines equally well. EMBO J. 31, 162–174 (2012).
pubmed: 22002536
doi: 10.1038/emboj.2011.367
Kim, E. et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27, 617–630 (2015).
pubmed: 25965569
pmcid: 4429920
doi: 10.1016/j.ccell.2015.04.006
Zhang, J. et al. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc. Natl Acad. Sci. USA 112, E4726–4734 (2015).
pubmed: 26261309
pmcid: 4553800
Yoshimi, A. et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature 574, 273–277 (2019).
pubmed: 31578525
pmcid: 6858560
doi: 10.1038/s41586-019-1618-0
Madan, V. et al. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat. Commun. 6, 6042 (2015).
pubmed: 25586593
doi: 10.1038/ncomms7042
Inoue, D. et al. Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition. Nat. Genet. 53, 707–718 (2021).
pubmed: 33846634
pmcid: 8177065
doi: 10.1038/s41588-021-00828-9
Burge, C. B., Padgett, R. A. & Sharp, P. A. Evolutionary fates and origins of U12-type introns. Mol. Cell 2, 773–785 (1998).
pubmed: 9885565
doi: 10.1016/S1097-2765(00)80292-0
Tarn, W. Y., Yario, T. A. & Steitz, J. A. U12 snRNA in vertebrates: evolutionary conservation of 5′ sequences implicated in splicing of pre-mRNAs containing a minor class of introns. RNA 1, 644–656 (1995).
pubmed: 7489523
pmcid: 1369308
Suzuki, H. et al. Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature 574, 707–711 (2019).
pubmed: 31664194
pmcid: 7141958
doi: 10.1038/s41586-019-1650-0
Shuai, S. et al. The U1 spliceosomal RNA is recurrently mutated in multiple cancers. Nature 574, 712–716 (2019).
pubmed: 31597163
doi: 10.1038/s41586-019-1651-z
Bousquets-Munoz, P. et al. PanCancer analysis of somatic mutations in repetitive regions reveals recurrent mutations in snRNA U2. NPJ Genom. Med. 7, 19 (2022).
pubmed: 35288589
pmcid: 8921233
doi: 10.1038/s41525-022-00292-2
Kurtovic-Kozaric, A. et al. PRPF8 defects cause missplicing in myeloid malignancies. Leukemia 29, 126–136 (2015).
pubmed: 24781015
doi: 10.1038/leu.2014.144
Dvinge, H., Kim, E., Abdel-Wahab, O. & Bradley, R. K. RNA splicing factors as oncoproteins and tumour suppressors. Nat. Rev. Cancer 16, 413–430 (2016).
pubmed: 27282250
pmcid: 5094465
doi: 10.1038/nrc.2016.51
Hernandez, J. et al. Tumor suppressor properties of the splicing regulatory factor RBM10. RNA Biol. 13, 466–472 (2016).
pubmed: 26853560
pmcid: 4841610
doi: 10.1080/15476286.2016.1144004
Bechara, E. G., Sebestyen, E., Bernardis, I., Eyras, E. & Valcarcel, J. RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol. Cell 52, 720–733 (2013).
pubmed: 24332178
doi: 10.1016/j.molcel.2013.11.010
Ghigna, C. et al. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol. Cell 20, 881–890 (2005).
pubmed: 16364913
doi: 10.1016/j.molcel.2005.10.026
Goncalves, V. et al. Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells. RNA 20, 474–482 (2014).
pubmed: 24550521
pmcid: 3964909
doi: 10.1261/rna.041376.113
Tacke, R., Chen, Y. & Manley, J. L. Sequence-specific RNA binding by an SR protein requires RS domain phosphorylation: creation of an SRp40-specific splicing enhancer. Proc. Natl Acad. Sci. USA 94, 1148–1153 (1997).
pubmed: 9037021
pmcid: 19759
doi: 10.1073/pnas.94.4.1148
Xiao, S. H. & Manley, J. L. Phosphorylation–dephosphorylation differentially affects activities of splicing factor ASF/SF2. EMBO J. 17, 6359–6367 (1998).
pubmed: 9799243
pmcid: 1170960
doi: 10.1093/emboj/17.21.6359
Cao, S. et al. Discovery of driver non-coding splice-site-creating mutations in cancer. Nat. Commun. 11, 5573 (2020).
pubmed: 33149122
pmcid: 7642382
doi: 10.1038/s41467-020-19307-6
Mian, S. A. et al. SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment. Nat. Commun. 6, 10004 (2015).
pubmed: 26643973
doi: 10.1038/ncomms10004
Lee, S. C. et al. Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations. Cancer Cell 34, 225–241 (2018).
pubmed: 30107174
pmcid: 6373472
doi: 10.1016/j.ccell.2018.07.003
Taylor, J. et al. Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. Blood 136, 1477–1486 (2020).
pubmed: 32640014
pmcid: 7515689
doi: 10.1182/blood.2020006868
Zhou, Q. et al. A chemical genetics approach for the functional assessment of novel cancer genes. Cancer Res. 75, 1949–1958 (2015).
pubmed: 25788694
doi: 10.1158/0008-5472.CAN-14-2930
Lee, S. C. et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat. Med. 22, 672–678 (2016).
pubmed: 27135740
pmcid: 4899191
doi: 10.1038/nm.4097
Fei, D. L. et al. Wild-type U2AF1 antagonizes the splicing program characteristic of U2AF1-mutant tumors and is required for cell survival. PLoS Genet. 12, e1006384 (2016).
pubmed: 27776121
pmcid: 5077151
doi: 10.1371/journal.pgen.1006384
Kaida, D. et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat. Chem. Biol. 3, 576–583 (2007).
pubmed: 17643111
doi: 10.1038/nchembio.2007.18
Fan, L., Lagisetti, C., Edwards, C. C., Webb, T. R. & Potter, P. M. Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem. Biol. 6, 582–589 (2011).
pubmed: 21344922
pmcid: 3113647
doi: 10.1021/cb100356k
Kotake, Y. et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat. Chem. Biol. 3, 570–575 (2007).
pubmed: 17643112
doi: 10.1038/nchembio.2007.16
Hasegawa, M. et al. Identification of SAP155 as the target of GEX1A (herboxidiene), an antitumor natural product. ACS Chem. Biol. 6, 229–233 (2011).
pubmed: 21138297
doi: 10.1021/cb100248e
Yokoi, A. et al. Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS J. 278, 4870–4880 (2011).
pubmed: 21981285
doi: 10.1111/j.1742-4658.2011.08387.x
Cretu, C. et al. Structural basis of splicing modulation by antitumor macrolide compounds. Mol. Cell 70, 265–273 (2018).
pubmed: 29656923
doi: 10.1016/j.molcel.2018.03.011
Eskens, F. A. et al. Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin. Cancer Res. 19, 6296–6304 (2013).
pubmed: 23983259
doi: 10.1158/1078-0432.CCR-13-0485
Hong, D. S. et al. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest. New Drugs 32, 436–444 (2014).
pubmed: 24258465
doi: 10.1007/s10637-013-0046-5
Crews, L. A. et al. RNA splicing modulation selectively impairs leukemia stem cell maintenance in secondary human AML. Cell Stem Cell 19, 599–612 (2016).
pubmed: 27570067
pmcid: 5097015
doi: 10.1016/j.stem.2016.08.003
Seiler, M. et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat. Med. 24, 497–504 (2018).
pubmed: 29457796
pmcid: 6730556
doi: 10.1038/nm.4493
Steensma, D. P. et al. Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia 35, 3542–3550 (2021).
pubmed: 34172893
pmcid: 8632688
doi: 10.1038/s41375-021-01328-9
Ting, T. C. et al. Aryl sulfonamides degrade RBM39 and RBM23 by recruitment to CRL4–DCAF15. Cell Rep. 29, 1499–1510 (2019).
pubmed: 31693891
pmcid: 7950731
doi: 10.1016/j.celrep.2019.09.079
Han, T. et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science 356, eaal3755 (2017).
Du, X. et al. Structural basis and kinetic pathway of RBM39 recruitment to DCAF15 by a sulfonamide molecular glue E7820. Structure 27, 1625–1633 (2019).
pubmed: 31693911
doi: 10.1016/j.str.2019.10.005
Faust, T. B. et al. Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15. Nat. Chem. Biol. 16, 7–14 (2020).
pubmed: 31686031
doi: 10.1038/s41589-019-0378-3
Bussiere, D. E. et al. Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex. Nat. Chem. Biol. 16, 15–23 (2020).
pubmed: 31819272
doi: 10.1038/s41589-019-0411-6
Wang, E. et al. Targeting an RNA-binding protein network in acute myeloid leukemia. Cancer Cell 35, 369–384 (2019).
pubmed: 30799057
pmcid: 6424627
doi: 10.1016/j.ccell.2019.01.010
Assi, R. et al. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124, 2758–2765 (2018).
pubmed: 29660836
doi: 10.1002/cncr.31398
Jagtap, P. K. A. et al. Identification of phenothiazine derivatives as UHM-binding inhibitors of early spliceosome assembly. Nat. Commun. 11, 5621 (2020).
pubmed: 33159082
pmcid: 7648758
doi: 10.1038/s41467-020-19514-1
Kobayashi, A. et al. Identification of a small molecule splicing inhibitor targeting UHM domains. FEBS J. 289, 682–698 (2021).
pubmed: 34520118
doi: 10.1111/febs.16199
Chatrikhi, R. et al. A synthetic small molecule stalls pre-mRNA splicing by promoting an early-stage U2AF2–RNA complex. Cell Chem. Biol. 28, 1145–1157 (2021).
pubmed: 33689684
doi: 10.1016/j.chembiol.2021.02.007
Mathew, R. et al. Phosphorylation of human PRP28 by SRPK2 is required for integration of the U4/U6-U5 tri-snRNP into the spliceosome. Nat. Struct. Mol. Biol. 15, 435–443 (2008).
pubmed: 18425142
doi: 10.1038/nsmb.1415
Edmond, V. et al. Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J. 30, 510–523 (2011).
pubmed: 21157427
doi: 10.1038/emboj.2010.333
Musiani, D. et al. Proteomics profiling of arginine methylation defines PRMT5 substrate specificity. Sci. Signal. 12, eaat8388 (2019).
Fong, J. Y. et al. Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation. Cancer Cell 36, 194–209 (2019).
pubmed: 31408619
pmcid: 7194031
doi: 10.1016/j.ccell.2019.07.003
Radzisheuskaya, A. et al. PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia. Nat. Struct. Mol. Biol. 26, 999–1012 (2019).
pubmed: 31611688
pmcid: 6858565
doi: 10.1038/s41594-019-0313-z
Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723–1732 (2017).
pubmed: 29091570
doi: 10.1056/NEJMoa1702752
McDonald, C. M. et al. Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial. J. Neuromuscul. Dis. 8, 989–1001 (2021).
pubmed: 34120909
pmcid: 8673535
doi: 10.3233/JND-210643
Walker, A. R. et al. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Adv. 5, 2775–2787 (2021).
pubmed: 34251414
pmcid: 8288671
doi: 10.1182/bloodadvances.2021004233
Sha, D. et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 10, 1808–1825 (2020).
pubmed: 33139244
pmcid: 7710563
doi: 10.1158/2159-8290.CD-20-0522
Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353–1365 (2020).
pubmed: 32919526
doi: 10.1016/S1470-2045(20)30445-9
Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).
pubmed: 28596308
pmcid: 5576142
doi: 10.1126/science.aan6733
Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009–1021 (2017).
pubmed: 28694034
doi: 10.1016/S1470-2045(17)30516-8
Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
pubmed: 25765070
pmcid: 4993154
doi: 10.1126/science.aaa1348
Jayasinghe, R. G. et al. Systematic analysis of splice-site-creating mutations in cancer. Cell Rep. 23, 270–281 (2018).
pubmed: 29617666
pmcid: 6055527
doi: 10.1016/j.celrep.2018.03.052
Laumont, C. M. et al. Noncoding regions are the main source of targetable tumor-specific antigens. Sci. Transl. Med. 10, eaau5516 (2018).
Smart, A. C. et al. Intron retention is a source of neoepitopes in cancer. Nat. Biotechnol. 36, 1056–1058 (2018).
pubmed: 30114007
pmcid: 6226333
doi: 10.1038/nbt.4239
Wang, R. F. et al. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol. 161, 3598–3606 (1998).
pubmed: 9759882
Robbins, P. F. et al. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J. Immunol. 159, 303–308 (1997).
pubmed: 9200467
Ouspenskaia, T. et al. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat. Biotechnol. 40, 209–217 (2021).
pubmed: 34663921
doi: 10.1038/s41587-021-01021-3
Lu, S. X. et al. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell 184, 4032–4047 (2021).
pubmed: 34171309
doi: 10.1016/j.cell.2021.05.038
North, K. et al. Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01224-2 (2022).
doi: 10.1038/s41587-022-01224-2
pubmed: 35241838
Monteys, A. M. et al. Regulated control of gene therapies by drug-induced splicing. Nature 596, 291–295 (2021).
pubmed: 34321659
pmcid: 8966400
doi: 10.1038/s41586-021-03770-2
Steijger, T. et al. Assessment of transcript reconstruction methods for RNA-seq. Nat. Methods 10, 1177–1184 (2013).
pubmed: 24185837
pmcid: 3851240
doi: 10.1038/nmeth.2714
Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4, 1521 (2015).
pubmed: 26925227
doi: 10.12688/f1000research.7563.1
Zhang, C., Zhang, B., Lin, L. L. & Zhao, S. Evaluation and comparison of computational tools for RNA-seq isoform quantification. BMC Genomics 18, 583 (2017).
pubmed: 28784092
pmcid: 5547501
doi: 10.1186/s12864-017-4002-1
De Paoli-Iseppi, R., Gleeson, J. & Clark, M. B. Isoform age—splice isoform profiling using long-read technologies. Front. Mol. Biosci. 8, 711733 (2021).
pubmed: 34409069
pmcid: 8364947
doi: 10.3389/fmolb.2021.711733
Simpson, J. T. et al. Detecting DNA cytosine methylation using nanopore sequencing. Nat. Methods 14, 407–410 (2017).
pubmed: 28218898
doi: 10.1038/nmeth.4184
Lorenz, D. A., Sathe, S., Einstein, J. M. & Yeo, G. W. Direct RNA sequencing enables m
pubmed: 31624092
pmcid: 6913132
doi: 10.1261/rna.072785.119
Chen, S. Y., Deng, F., Jia, X., Li, C. & Lai, S. J. A transcriptome atlas of rabbit revealed by PacBio single-molecule long-read sequencing. Sci Rep. 7, 7648 (2017).
pubmed: 28794490
pmcid: 5550469
doi: 10.1038/s41598-017-08138-z
Kim, J. A. et al. Genome-wide transcriptome profiling of the medicinal plant Zanthoxylum planispinum using a single-molecule direct RNA sequencing approach. Genomics 111, 973–979 (2019).
pubmed: 30003944
doi: 10.1016/j.ygeno.2018.06.004
Roach, N. P. et al. The full-length transcriptome of C. elegans using direct RNA sequencing. Genome Res. 30, 299–312 (2020).
pubmed: 32024661
pmcid: 7050520
doi: 10.1101/gr.251314.119
Lagarde, J. et al. High-throughput annotation of full-length long noncoding RNAs with capture long-read sequencing. Nat. Genet. 49, 1731–1740 (2017).
pubmed: 29106417
pmcid: 5709232
doi: 10.1038/ng.3988
Gupta, I. et al. Single-cell isoform RNA sequencing characterizes isoforms in thousands of cerebellar cells. Nat. Biotechnol. 36, 1197–1202 (2018).
doi: 10.1038/nbt.4259
Singh, M. et al. High-throughput targeted long-read single cell sequencing reveals the clonal and transcriptional landscape of lymphocytes. Nat. Commun. 10, 3120 (2019).
pubmed: 31311926
pmcid: 6635368
doi: 10.1038/s41467-019-11049-4